ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 1.16 | -0.43 | 0.54 |
| FCF Yield | 5.17% | -0.46% | -4.43% | -3.38% |
| EV / EBITDA | 27.69 | -73.68 | -11.38 | -21.87 |
| Quality | ||||
| ROIC | 24.92% | -17.48% | -47.99% | -27.89% |
| Gross Margin | 91.46% | 93.70% | 98.03% | 96.05% |
| Cash Conversion Ratio | 0.70 | -0.27 | 0.53 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.80% | 14.48% | 5.40% | 12.61% |
| Free Cash Flow Growth | 773.27% | 79.53% | 10.05% | 11.81% |
| Safety | ||||
| Net Debt / EBITDA | -2.67 | 1.94 | 0.24 | 0.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.73 | 1.28 | 1.53 | 2.43 |
| Cash Conversion Cycle | 65.57 | 197.30 | -174.86 | 68.43 |